Read by QxMD icon Read

Nephrology, Dialysis, Transplantation

David A Bushinsky, Glenn M Chertow, Sunfa Cheng, Hongjie Deng, Nelson Kopyt, Kevin J Martin, Anjay Rastogi, Pablo Ureña-Torres, Marc Vervloet, Geoffrey A Block
BACKGROUND: Secondary hyperparathyroidism (sHPT), a common complication of chronic kidney disease, is characterized by elevated serum parathyroid hormone (PTH). Etelcalcetide is an intravenous calcimimetic that increases sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. This open-label extension (OLE) trial evaluated the long-term effects of etelcalcetide for sHPT treatment in patients receiving hemodialysis. METHODS: This 52-week, multicenter, single-arm OLE enrolled patients from three parent trials: two randomized, double-blind, placebo-controlled trials and one open-label, single-arm, 'switch' study from cinacalcet to etelcalcetide...
March 11, 2019: Nephrology, Dialysis, Transplantation
Marie-Cécile Fournier, Yohann Foucher, Paul Blanche, Christophe Legendre, Sophie Girerd, Marc Ladrière, Emmanuel Morelon, Fanny Buron, Lionel Rostaing, Nassim Kamar, Georges Mourad, Valérie Garrigue, Grégoire Couvrat-Desvergnes, Magali Giral, Etienne Dantan
BACKGROUND: Informing kidney transplant recipients of their prognosis and disease progression is of primary importance in a patient-centred vision of care. By participating in decisions from the outset, transplant recipients may be more adherent to complex medical regimens due to their enhanced understanding. METHODS: We proposed to include repeated measurements of serum creatinine (SCr), in addition to baseline characteristics, in order to obtain dynamic predictions of the graft failure risk that could be updated continuously during patient follow-up...
March 11, 2019: Nephrology, Dialysis, Transplantation
Rukshana Shroff, Francis Calder, Sevcan Bakkaloğlu, Evi V Nagler, Sam Stuart, Lynsey Stronach, Claus P Schmitt, Karl H Heckert, Pierre Bourquelot, Ann-Marie Wagner, Fabio Paglialonga, Sandip Mitra, Constantinos J Stefanidis
BACKGROUND: There are three principle forms of vascular access available for the treatment of children with end stage kidney disease (ESKD) by haemodialysis: tunnelled catheters placed in a central vein (central venous lines, CVLs), arteriovenous fistulas (AVF), and arteriovenous grafts (AVG) using prosthetic or biological material. Compared with the adult literature, there are few studies in children to provide evidence based guidelines for optimal vascular access type or its management and outcomes in children with ESKD...
March 11, 2019: Nephrology, Dialysis, Transplantation
Rajiv Agarwal
BACKGROUND: Chronic kidney disease (CKD) is characterized by accelerated aging, but the age-related changes in body composition and its modification by sex and race are unclear. METHODS: We assembled a cohort of 516 patients with CKD and 45 healthy controls and serially measured body composition using air-displacement plethysmography for up to 6 years. Mixed models were used to evaluate simultaneously the baseline and longitudinal changes in body composition as influenced by age, sex and race...
March 7, 2019: Nephrology, Dialysis, Transplantation
Eleni Frangou, Agathi Varnavidou-Nicolaidou, Panayiotis Petousis, Andreas Soloukides, Elena Theophanous, Isavella Savva, Nicos Michael, Elpida Toumasi, Dora Georgiou, Galatia Stylianou, Richard Mean, Natasa Anastasiadou, Yiannis Athanasiou, Michalis Zavros, Kyriacos Kyriacou, Constantinos Deltas, Vassilis Hadjianastassiou
BACKGROUND: Complement factor H-related protein 5 (CFHR5) nephropathy is an inherited renal disease characterized by microscopic and synpharyngitic macroscopic haematuria, C3 glomerulonephritis and renal failure. It is caused by an internal duplication of exons 2-3 within the CFHR5 gene resulting in dysregulation of the alternative complement pathway. The clinical characteristics and outcomes of transplanted patients with this rare familial nephropathy remain unknown. METHODS: This is a retrospective case series study of 17 kidney transplant patients with the established founder mutation, followed-up over a span of 30 years...
March 7, 2019: Nephrology, Dialysis, Transplantation
Francesco Locatelli, Lucia Del Vecchio
Prolyl-hydroxylase (PHD) inhibitors (PHD-I) are the most appealing drugs undergoing clinical development for the treatment of anaemia in patients with chronic kidney disease. PHD inhibition mimics the exposure of the body to hypoxia and activates the hypoxia-inducible factor system. Among many other pathways, this activation promotes the production of endogenous erythropoietin (EPO) and the absorption and mobilization of iron. PHD-I are given orally and, differing from erythropoiesis-stimulating agents (ESAs), they correct and maintain haemoglobin levels by stimulating endogenous EPO production...
March 7, 2019: Nephrology, Dialysis, Transplantation
Adrian M Whelan, Elaine Ku
No abstract text is available yet for this article.
March 5, 2019: Nephrology, Dialysis, Transplantation
Allyson Hart, Kirsten L Johansen
No abstract text is available yet for this article.
March 4, 2019: Nephrology, Dialysis, Transplantation
Chava L Ramspek, Ype de Jong, Friedo W Dekker, Merel van Diepen
BACKGROUND: Prediction tools that identify chronic kidney disease (CKD) patients at a high risk of developing kidney failure have the potential for great clinical value, but limited uptake. The aim of the current study is to systematically review all available models predicting kidney failure in CKD patients, organize empirical evidence on their validity and ultimately provide guidance in the interpretation and uptake of these tools. METHODS: PubMed and EMBASE were searched for relevant articles...
March 4, 2019: Nephrology, Dialysis, Transplantation
Bruno Watschinger, Klemens Budde, Marta Crespo, Uwe Heemann, Luuk Hilbrands, Umberto Maggiore, Christophe Mariat, Rainer Oberbauer, Gabriel C Oniscu, Licia Peruzzi, Søren S Sorensen, Ondrej Viklicky, Daniel Abramowicz
Current proposals for waiting times for a renal transplant after malignant disease may not be appropriate. New data on malignancies in end-stage renal disease and recent diagnostic and therapeutic options should lead us to reconsider our current practice.
March 4, 2019: Nephrology, Dialysis, Transplantation
Kirsten L Johansen
No abstract text is available yet for this article.
March 1, 2019: Nephrology, Dialysis, Transplantation
James Fotheringham, Ayesha Sajjad, Vianda S Stel, Keith McCullough, Angelo Karaboyas, Martin Wilkie, Brian Bieber, Bruce M Robinson, Ziad A Massy, Kitty J Jager
BACKGROUND: On the first haemodialysis (HD) day after the 2-day break in three times a week (3×W) in-centre HD, mortality and hospitalization are higher. If longer HD sessions prescribed 3×W is associated with a reduction in these events is unknown. METHODS: HD session length in 19 557 prevalent European in-centre 3×W HD patients participating in the Dialysis Outcomes and Practice Patterns Study (1998-2011) were categorized into <200, 200-225, 226-250 or >250 min...
February 28, 2019: Nephrology, Dialysis, Transplantation
Mark Lambie, Lucy Teece, David W Johnson, Michaela Petrie, Robert Mactier, Ivonne Solis-Trapala, John Belcher, Hilary L Bekker, Martin Wilkie, Ken Tupling, Louise Phillips-Darby, Simon J Davies
BACKGROUND: Risk of encapsulating peritoneal sclerosis (EPS) is strongly associated with the duration of peritoneal dialysis (PD), such that patients who have been on PD for some time may consider elective transfer to haemodialysis to mitigate the risk of EPS. There is a need to determine this risk to better inform clinical decision making, but previous studies have not allowed for the competing risk of death. METHODS: This study included new adult PD patients in Australia and New Zealand (ANZ; 1990-2010) or Scotland (2000-08) followed until 2012...
February 28, 2019: Nephrology, Dialysis, Transplantation
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque, Gérard M London, Ziad Massy, Petro Ruggenenti, Esteban Porrini, Andrzej Wiecek, Carmine Zoccali, Francesca Mallamaci, Mads Hornum
No abstract text is available yet for this article.
February 28, 2019: Nephrology, Dialysis, Transplantation
Davide Viggiano, Anna Capasso, Giovambattista Capasso
No abstract text is available yet for this article.
February 27, 2019: Nephrology, Dialysis, Transplantation
Carmine Zoccali, Peter J Blankestijn, Annette Bruchfeld, Giovambattista Capasso, Danilo Fliser, Denis Fouque, Dimitrios Goumenos, Markus Ketteler, Ziad Massy, Ivan Rychlık, Maria Soler, Kate Stevens, Goce Spasovski, Christoph Wanner
The exclusion of chronic kidney disease (CKD) patients from clinical trials-particularly cardiovascular trials-remains a long-standing, unsolved problem, which prevents the optimization of clinical care in these patients. The situation recalls the insufficient recruitment of women in cardiovascular trials until the 1980s, a problem that was only resolved following regulatory interventions. Regulatory agencies are in a unique position to promote recruitment of CKD patients in clinical trials. The main stakeholders, namely patients' associations and scientific societies, should make major lobbying efforts to persuade these agencies that the issue is an absolute public health priority...
February 27, 2019: Nephrology, Dialysis, Transplantation
Dervla M Connaughton, Friedhelm Hildebrandt
A large fraction of early-onset chronic kidney disease (CKD) is known to be monogenic in origin. To date, ∼450 monogenic (synonymous with single-gene disorders) genes, if mutated, are known to cause CKD, explaining ∼30% of cases in pediatric cohorts and ∼5-30% in adult cohorts. However, there are likely hundreds of additional monogenic nephropathy genes that may be revealed by whole-exome or -genome sequencing. Although the discovery of novel CKD-causing genes has accelerated, significant challenges in adult populations remain due to broad phenotypic heterogeneity together with variable expressivity, incomplete penetrance or age-related penetrance of these genes...
February 26, 2019: Nephrology, Dialysis, Transplantation
Vandana Dua Niyyar
No abstract text is available yet for this article.
February 26, 2019: Nephrology, Dialysis, Transplantation
Branko Braam, Chung Foon Lai, Joseph Abinader, Aminu K Bello
BACKGROUND: Hypertension is prevalent in patients with chronic kidney disease (CKD) and is related to extracellular fluid volume (ECFV) expansion. Arterial stiffening is another implication of CKD that can be caused by ECFV expansion. In this study, we hypothesized that CKD patients with uncontrolled hypertension are more likely to be fluid volume expanded than normotensive patients, which in turn is associated with increased arterial stiffness. METHODS: Adult hypertensive patients with mild-severe CKD (n = 82) were recruited...
February 25, 2019: Nephrology, Dialysis, Transplantation
Carlo Basile, Francesco Gaetano Casino
No abstract text is available yet for this article.
February 25, 2019: Nephrology, Dialysis, Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"